N/A
Completed N=349
Motivation, Syringe Exchange, and COVID-19
COVID-19 Pandemic
Source: ClinicalTrials.gov NCT05534061 ↗
Enrolled (actual)
349
Serious AEs
0.0%
Results posted
Feb 2024
Primary outcomePrimary: SARS-CoV-2 Testing — 54; 53; 123; 119 Participants — p=.944
Summary
People who inject drugs (PWIDs) are highly vulnerable to SARS-CoV-2 infection and to the disease caused by SARS-CoV-2, coronavirus disease 2019 (COVID-19), however, rates of SARS-CoV-2 testing and vaccination uptake -vital to mitigating the spread of COVID-19 and achieving herd immunity - are lower among PWIDs compared to the general population. Building on our Phase I Rapid Acceleration of Diagnostics project, which found that contingency management (CM) increased testing utilization among PWIDs, the proposed project evaluates the comparative effectiveness of CM versus CM plus a brief motivational enhancement intervention on SARS-CoV-2 testing and vaccination uptake among PWIDs. This project has the potential to reduce COVID-19 health disparities among PWIDs and to decrease population level COVID-19 morbidity and mortality.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY SARS-CoV-2 Testing |
46; 46; 131; 126 | .952 |
| SECONDARY COVID-19 Vaccination |
19; 5; 158; 167 | .008 sig |
Eligibility Criteria
Inclusion Criteria
- 18 and older, understand English
Exclusion Criteria
- none
Data sourced from ClinicalTrials.gov (NCT05534061). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.